Patents by Inventor Gary J. Kurtzman

Gary J. Kurtzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Induction of immune response to antigens expressed by recombinant adeno-associated virus
    Patent number: 6242426
    Abstract: The present invention relates generally to immunization methods using recombinant viral vectors. In particular, the invention relates to methods and compositions for immunizing a subject with a nucleic acid molecule encoding an antigen of interest, wherein the nucleic acid molecule is delivered to the subject via a recombinant AAV virion.
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: June 5, 2001
    Assignee: Avigen, Inc.
    Inventors: Gary J. Kurtzman, Edgar G. Engelman, Greg M. Podsakoff, Dirk G. Brockstedt
  • Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors
    Publication number: 20010001661
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.
    Type: Application
    Filed: January 4, 2001
    Publication date: May 24, 2001
    Applicant: Avigen, Inc.
    Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
  • Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
    Patent number: 6218180
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 17, 2001
    Assignee: Avigen, Inc.
    Inventors: Gary J. Kurtzman, Peter C. Colosi, Jun Yoshida, Masaaki Mizuno, Hideho Okada
  • Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors
    Patent number: 6211163
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: April 3, 2001
    Assignee: Avigen, Inc.
    Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
  • Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
    Patent number: 5962313
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: October 5, 1999
    Assignees: Avigen, Inc., Johns Hopkins University
    Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
  • Adeno-associated virus vectors comprising a first and second nucleic acid sequence
    Patent number: 5952221
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: September 14, 1999
    Assignee: Avigen, Inc.
    Inventors: Gary J. Kurtzman, Peter C. Colosi, Jun Yoshida, Masaaki Mizuno, Hideho Okada
  • Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
    Patent number: 5858351
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: January 12, 1999
    Assignees: Avigen, Inc., Johns Hopkins University
    Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
  • Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
    Patent number: 5846528
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: December 8, 1998
    Assignees: Avigen, Inc., Johns Hopkins University
    Inventors: Gregory M. Podsakoff, Gary J. Kurtzman